Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents

被引:93
作者
Esnault, VLM [1 ]
Ekhlas, A [1 ]
Delcroix, C [1 ]
Moutel, MG [1 ]
Nguyen, JM [1 ]
机构
[1] Nantes Univ Hosp, Nephrol & Clin Immunol Dept, Nantes, France
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2005年 / 16卷 / 02期
关键词
D O I
10.1681/ASN.2004060505
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics may exert synergistic antiproteinuric effects. Eighteen patients with a proteinuria >1 g/24 h after 6 mo of treatment with ramipril at 5 mg/d were assigned to receive in random order ramipril at 10 mg/d, valsartan at 160 mg/d, or combined ramipril at 5 mg/d and valsartan at 80 mg/d in addition to their antihypertensive treatment. The treatment periods lasted 4 wk and were separated by a 4-wk washout with ramipril at 5 mg/d. At the end of this crossover sequence, patients received combined ramipril at 5 mg/d, valsartan at 80 mg/d, and an increased furosemide dosage for an additional 4-wk period. The primary end point was the urinary protein/creatinine ratio for two 24-h urine collections at the end of each treatment period. No significant differences were noted between the study end points of the ramipril 10, valsartan 160, and combined ramipril 5 and valsartan 80 treatment groups. However, the urinary protein/creatinine ratio was lower with combined ramipril 5 and valsartan 80-increased furosemide dosage than with valsartan 160 and combined ramipril 5 and valsartan 80, with a similar tendency compared with ramipril 10. Combined ramipril 5 and valsartan 80-increased furosemide dosage decreased systolic home BP and increased serum creatinine but did not significantly increase the number of symptomatic hypotension cases compared with the other three treatments. Thus, in patients with severe proteinuria and hypertension, a cautious increase in diuretic dosage in addition to combined angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decreases proteinuria and BP but may expose the patient to prerenal failure.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 41 条
[1]   Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-β levels [J].
Agarwal, R ;
Siva, S ;
Dunn, SR ;
Sharma, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (03) :486-492
[2]   Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection:: The case for AT1 receptor antagonist [J].
Berl, T .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (01) :S71-S76
[3]   Interactions of transforming growth factor-β and angiotensin II in renal fibrosis [J].
Border, WA ;
Noble, NA .
HYPERTENSION, 1998, 31 (01) :181-188
[4]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[5]   The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide [J].
Buter, H ;
Hemmelder, MH ;
Navis, G ;
de Jong, PE ;
de Zeeuw, D .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (07) :1682-1685
[6]   Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies [J].
Campbell, R ;
Sangalli, F ;
Perticucci, E ;
Aros, C ;
Viscarra, C ;
Perna, A ;
Remuzzi, A ;
Bertocchi, F ;
Fagiani, L ;
Remuzzi, G ;
Ruggenenti, P .
KIDNEY INTERNATIONAL, 2003, 63 (03) :1094-1103
[7]   Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. [J].
Chrysostomou, A ;
Becker, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :925-926
[8]   Avian integumentary surgery [J].
Ferrell, ST .
SEMINARS IN AVIAN AND EXOTIC PET MEDICINE, 2002, 11 (03) :125-135
[9]   THE ANTIPROTEINURIC EFFECT OF ACE-INHIBITION MEDIATED BY INTERFERENCE IN THE RENIN-ANGIOTENSIN SYSTEM [J].
GANSEVOORT, RT ;
DEZEEUW, D ;
DEJONG, PE .
KIDNEY INTERNATIONAL, 1994, 45 (03) :861-867
[10]   Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro [J].
Haugen, EN ;
Croatt, AJ ;
Nath, KA .
KIDNEY INTERNATIONAL, 2000, 58 (01) :144-152